Tonix Pharmaceuticals Presents Positive Preclinical Data on TNX-1700 for Gastric Cancer at AACR 2025

Tonix Pharmaceuticals Holding Corp.

At AACR 2025, Tonix showed TFF2-MSA (murine TNX-1700) plus anti-PD1 inhibited gastric tumor growth by 78.29% in mouse models.
Combination therapy activated cancer-killing CD8+ T cells and reduced immunosuppressive PMN-MDSCs in the tumor microenvironment.
TNX-1700 (hTFF2-HAS) is in preclinical development for gastric and colorectal cancers, with further studies planned.
Data demonstrated TFF2-MSA outperformed CXCR4 antagonist AMD3100 in reducing PMN-MDSC generation.
TFF2 reduction correlated with elevated PMN-MDSCs in gastric cancer patients, supporting the therapeutic target.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.